Wealth Architects LLC Trims Stock Position in Cencora, Inc. (NYSE:COR)

Wealth Architects LLC cut its stake in Cencora, Inc. (NYSE:COR) by 7.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,377 shares of the company’s stock after selling 106 shares during the period. Wealth Architects LLC’s holdings in Cencora were worth $310,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of COR. Price T Rowe Associates Inc. MD purchased a new stake in shares of Cencora in the 1st quarter valued at about $2,183,619,000. JPMorgan Chase & Co. purchased a new stake in Cencora in the 1st quarter valued at $1,199,695,000. Boston Partners acquired a new stake in Cencora during the 1st quarter worth $1,001,269,000. Capital Research Global Investors purchased a new position in Cencora during the 1st quarter worth $650,424,000. Finally, Bessemer Group Inc. acquired a new position in Cencora in the first quarter valued at $556,245,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. Evercore ISI dropped their price target on Cencora from $270.00 to $250.00 and set an “outperform” rating on the stock in a research report on Tuesday, October 8th. Wells Fargo & Company upped their price target on Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research note on Thursday, August 1st. JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research report on Wednesday, August 21st. Leerink Partners cut their price objective on shares of Cencora from $277.00 to $275.00 and set an “outperform” rating for the company in a research report on Monday, October 7th. Finally, StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Three research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, Cencora currently has an average rating of “Moderate Buy” and an average price target of $259.44.

Insider Buying and Selling at Cencora

In other news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the sale, the chairman now owns 285,088 shares of the company’s stock, valued at $67,223,750.40. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 15.80% of the stock is currently owned by corporate insiders.

Cencora Stock Performance

Shares of COR opened at $245.38 on Thursday. The company has a quick ratio of 0.55, a current ratio of 0.89 and a debt-to-equity ratio of 3.93. Cencora, Inc. has a 52-week low of $191.11 and a 52-week high of $247.66. The company has a 50-day simple moving average of $231.57 and a 200-day simple moving average of $230.64. The company has a market capitalization of $48.35 billion, a PE ratio of 26.64, a P/E/G ratio of 1.49 and a beta of 0.44.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.